Prostaglandin E2 mediates IL-1β-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors

Journal of Immunology

Volumn 180, Issue 1, 2008, Pages 637-646

  White, Kimberly E ^a   Ding, Qiang ^a   Moore, Bethany B ^c   Peters Golden, Marc ^c   Ware, Lorraine B ^d   Matthay, Michael A ^e   Olman, Mitchell A ^a,b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTAPROST; CYCLIC AMP; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; PERTUSSIS TOXIN; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; SULPROSTONE; MESSENGER RNA; MITOGENIC AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN EP3 RECEPTOR; PTGS2 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT; AGED; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN CELL; LUNG EDEMA; LUNG FIBROBLAST; LUNG FLUID; MALE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; ADULT RESPIRATORY DISTRESS SYNDROME; DRUG EFFECT; EXUDATE; FIBROBLAST; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; CELL PROLIFERATION; CYCLOOXYGENASE 2; DINOPROSTONE; EXUDATES AND TRANSUDATES; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MITOGENS; PULMONARY EDEMA; RECEPTORS, PROSTAGLANDIN E; RESPIRATORY DISTRESS SYNDROME, ADULT; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 40449095435     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.1.637     Document Type: Article

References (74)

1. Ware, L. B., and M. A. Matthay. 2000. Medical progress: the acute respiratory distress syndrome. N. Engl. J. Med. 342: 1334-1349.
2. Goss, C. H., R. G. Brower, L. D. Hudson, and G. D. Rubenfeld. 2003. Incidence of acute lung injury in the United States. Crit. Care Med. 31: 1607-1611.
3. Rubenfeld, G. D., E. Caldwell, E. Peabory, J. Weaver, D. P. Martin, M. Neff, E. J. Stern, and L. D. Hudson. 2005. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 353: 1685-1693.
4. Bitterman, P. B. 1992. Pathogenesis of fibrosis in acute lung injury. Am. J. Med. 92: 39S-43S.
5. Raghu, G., L. J. Striker, L. D. Hudson, and G. E. Striker. 1985. Extracellular matrix in normal and fibrotic human lungs. Am. Rev. Resp. Dis. 131: 281-289.
6. Olman, M. A. 2003. The fibroproliferative phase of acute lung injury. In Acute Respiratory Distress Syndrome. M. Matthay and C. Lenfant, eds. Marcel Dekker, Seattle, Washington, pp. 313-354.
7. Olman, M., N. Mackman, C. Gladson, K. Moser, and D. Loskutoff. 1995. Changes in procoagulant and fibrinolytic gene expression during bleomycin induced lung injury in the mouse. J. Clin. Invest. 96: 1621-1630.
8. Olman, M. A., W. L. Simmons, D. J. Pollman, A. Y. Loftis, A. Bini, E. J. Miller, G. M. Fuller, and K. Rivera. 1996. Polymerization of fibrinogen in murine bleomycin-induced lung injury. Am. J. Physiol. 271: L519-L526.
9. Bachofen, A., and E. R. Weibel. 1977. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am. Rev. Resp. Dis. 116: 589-615.
10. Fukuda, Y., M. Ishizaki, Y. Masuda, G. Kimura, O. Kawanami, and Y. Masugi. 1987. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am. J. Pathol. 126: 171-182.
11. Clark, J. G., J. A. Milberg, K. P. Steinberg, and L. D. Hudson. 1995. Type III procollagen peptide in the adult respiratory distress syndrome. Ann. Intern. Med. 122: 17-23.
12. Chesnutt, A. N., M. A. Matthay, F. A. Tibayan, and J. G. Clark. 1997. Early detection of type III procollagen peptide in acute lung injury. Am. J. Respir. Crit. Care Med. 156: 840-845.
13. Pugin, J., G. M. Verghese, M. C. Widmer, and M. A. Matthay. 1999. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit. Care Med. 27: 304-312.
14. Marshall, R. P., G. Bellingan, S. Webb, A. Puddicombe, N. Goldsack, R. J. McAnulty, and G. J. Laurent. 2000. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am. J. Respir. Crit. Care Med. 162: 1783-1788.
15. Synder, L. S., M. I. Hertz, M. S. Peterson, K. R. Harmon, W. A. Marinelli, C. A. Henke, J. R. Greenheck, B. Chen, and P. B. Bitterman. 1991. Acute lung injury: pathogenesis of intraalveolar fibrosis. J. Clin. Invest. 88: 663-673.
16. Chen, B., V. Polunovsky, J. White, B. Blazar, R. Nakhleh, J. Jessurun, M. Peterson, and P. Bitterman. 1992. Mesenchymal cells isolated after acute lung injury manifest an enhanced proliferative phenotype. J. Clin. Invest. 90: 1778-1785.
17. Pittet, J. F., R. C. Mackersie, T. R. Martin, and M. A. Matthay. 1997. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med. 155: 1187-1205.
18. Suter, P. M., S. M. Suter, E. Girardin, P. Roux-Lombard, G. E. Grau, and J. M. Dayer. 1992. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am. Rev. Resp. Dis. 145: 1016-1022.
19. Goodman, R. B., R. M. Strieter, D. P. Martin, K. P. Steinberg, J. A. Milberg, R. J. Maunder, S. L. Kunkel, A. Walz, L. D. Hudson, and T. R. Martin. 1996. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 154: 602-611.
20. Gaggar, A., and M. A. Olman. 2006. Biologic markers of mortality in acute lung injury. Clin. Chimica Acta 372: 24-32.
21. Kolb, M., P. J. Margetts, D. C. Anthony, F. Pitossi, and J. Gauldie. 2001. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest. 107: 1529-1536.
22. Olman, M. A., K. E. White, L. Ware, W. L. Simmons, J. Pugin, E. N. Benveniste, M. A. Matthay, and S. Zhu. 2004. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1β-induced IL-6 expression. J. Immunol. 172: 2668-2677.
23. 2. Am. J. Physiol. 284: L342-L349.
24. 2 subtype receptors in serum-induced 3T6 fibroblast cycle progression and proliferation. Am. J. Physiol. 282: C280-C288.
25. Narumiya, S., Y. Sugimoto, and F. Ushkubi. 1999. Prostanoid receptors: structures, properties, and functions. Physiol. Rev. 79: 1193-1226.
26. 2 synthesis by human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 12: 358-365.
27. Ozaki, T., S. I. Rennard, and R. G. Crystal. 1987. Cyclooxygenase metabolites are compartmentalized in the human lower respiratory tract. J. Appl. Physiol. 62: 219-222.
28. Borok, Z., A. Gillissen, R. Buhl, R. F. Hoyt, R. C. Hubbard, T. Ozaki, S. I. Rennard, and R. G. Crystal. 1991. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am. Rev. Respir. Dis. 144: 1080-1084.
29. 2 and to express cyclooxygenase-2. J. Clin. Invest. 95: 1861-1868.
30. 2 production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am. J. Respir. Cell Mol. Biol. 22: 628-634.
31. Jordana, M., J. Schulman, C. McSharry, L. B. Irving, M. T. Newhouse, G. Jordana, and J. Gauldie. 1988. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am. Rev. Resp. Dis. 137: 579-584.
32. Wilson, R. J., S. A. Rhodes, R. L. Wood, V. J. Shield, L. S. Noel, D. W. Gray, and H. Giles. 2004. Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur. J. Pharmacol. 501: 49-58.
33. Hata, A. N., and R. M. Breyer. 2004. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103: 147-166.
34. Breyer, R. M., C. Bagdassarian, S. Myers, and M. Breyer. 2001. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41: 661-690.
35. Funk, C. D., L. Furci, G. A. Fitzgerald, R. Grygorczy, C. Rochette, M. A. Bayne, M. Abramovitz, M. Adam, and K. M. Metters. 1993. Cloning and expression of cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem. 268: 26767-26772.
36. 2. J. Immunol. 174: 5466-5649.
37. 2. J. Immunol. 155: 4437-4444.
38. Matthay, M. A., and J. P. Wiener-Kronish. 1999. Intact epithelial barrier function is critical for the resolution of alveolar edema in humans. Am. Rev. Resp. Dis. 142: 1250-1257.
39. Artigas, A., G. R. Bernard, J. Carlet, D. Dreyfuss, L. Gattinoni, L. Hudson, M. Lamy, J. J. Marini, M. A. Matthay, M. Pinsky, R. Spracc, and P. M. Suter. 1998. The American-European consensus conference on ARDS, part 2. Am. J. Respir. Crit. Care Med. 157: 1332-1347.
40. Le Gall, J. R., S. Lemenshow, and F. Saulnier. 1993. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. J. Am. Med. Assoc. 270: 2957-2963.
41. Verghese, G. M., L. B. Ware, B. A. Matthay, and M. A. Matthay. 1999. Alveolar epithelial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema. J. Appl. Physiol. 87: 1301-1312.
42. Petering, H., J. Kohl, A. Weyergraf, Y. Dulkys, D. Kimmig, R. Smolarski, A. Kapp, and J. Elsner. 2000. Characterization of synthetic C3a analog peptides on human eosinophils in comparison to the native complement component C3a. J. Immunol. 164: 3783-3789.
43. Prabhakaran, P., L. B. Ware, K. E. White, M. T. Cross, M. A. Matthay, and M. A. Olman. 2003. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am. J. Physiol. 285: L20-L28.
44. Zar, J. H. 1984. Biostatistical Analysis. Prentice-Hall, Englewood Cliffs.
45. Sanchez, T., and J. J. Moreno. 2006. GR 63799X, an EP3 receptor agonist, induced S phase arrest and 3T6 fibroblast growth inhibition. Eur. J. Pharmacol. 529: 16-23.
46. Park, W. Y., R. B. Goodman, K. P. Steinberg, J. T. Ruzinski, F. Radella, D. R. Park, J. Pugin, S. J. Skerrett, L. D. Hudson, and T. R. Martin. 2001. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 164: 1896-1903.
47. Elias, J. A. 1988. Tumor necrosis factor interacts with interleukin-1 and interferons to inhibit fibroblast proliferation via fibroblast prostaglandin-dependent and -independent mechanisms. Am. Rev. Respir. Dis. 138: 652-658.
48. Keerthisingam, C. B., R. G. Jenkins, N. K. Harrison, N. A. Hernandez-Rodriguez, H. Booth, G. J. Laurent, S. L. Hart, M. L. Foster, and R. J. McAnulty. 2001. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 158: 1411-1422.
49. Matthay, M. A., W. L. Eschenbacher, and E. J. Goetzl. 1984. Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with adult respiratory distress syndrome. J. Clin. Immunol. 4: 479-483.
50. Lonnemann, G., L. Shapiro, G. Engler-Blum, G. A. Muller, K. M. Koch, and C. A. Dinarello. 1995. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int. 47: 837-844.
51. Bitterman, P. B., M. D. Wewers, S. I. Rennard, S. Adelberg, and R. G. Crystal. 1986. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J. Clin. Invest. 77: 700-708.
52. Elias, J. A., M. D. Rossman, R. B. Zurier, and R. P. Daniele. 1985. Human alveolar macrophage inhibition of lung fibroblast growth: a prostaglandin-dependent process. Am. Rev. Respir. Dis. 131: 94-99.
53. Liu, X., R. S. Ostrom, and P. A. Insel. 2004. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am. J. Physiol. 286: C1089-C1099.
54. 2 inhibits fibroblast to myofibroblast transition via E prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. 29: 537-544.
55. 2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am. J. Respir. Cell Mol. Biol. 27: 752-758.
56. 2 inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am. J. Respir. Cell Mol. Biol. 32: 135-141.
57. 2 inhibits fibroblast chemotaxis. Am. J. Physiol. 281: L1257-L1263.
58. 2, and NO acting through separate parallel pathways. Am. J. Respir. Cell Mol. Biol. 25: 245-253.
59. Kiriyama, M., F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya. 1997. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 122: 217-224.
60. Sugimoto, Y., S. Narumiya, and A. Ichikawa. 2000. Distribution and function of prostanoid receptors: studies from knockout mice. Prog. Lipid Res. 39: 289-314.
61. Coquette, A., J.-M. Boeynaems, and B. Vray. 1992. Eicosanoids modulate CR1- and Fc-dependent bacterial phagocytosis. Eur. J. Pharmacol. 226: 1-4.
62. Razin, E., S. Bauminger, and A. Globerson. 1978. Effect of prostaglandins on phagocytosis of sheep erythrocytes by mouse peritoneal macrophages. J. Recticul. Soc. 23: 237-242.
63. 2 receptor subtypes in M-1 mouse CCD cells. Am. J. Physiol. 281: F123-F132.
64. Ikegami, R., Y. Sugimoto, E. Segi, M. Katsuyama, H. Karahashi, R. Amano, T. Maruyama, H. Yamane, S. Tsuchiya, and A. Ichikawa. 2001. The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. J. Immunol. 166: 4689-4696.
65. Handler, J. A., R. M. Danilowicz, and T. E. Eling. 1990. Mitogenic signaling by epidermal growth factor (EGF), but not platelet-derived growth factor, requires arachidonic acid metabolism in BALB/c 3T3 cells. J. Biol. Chem. 265: 3669-3673.
66. 2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8: 289-293.
67. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J. Biol. Chem. 278: 35451-35457.
68. 2. J. Biol. Chem. 277: 2614-2619.
69. 2 and cAMP and suppresses fibroblast proliferation and collagen production. J. Biol. Chem. 257: 8098-8105.
70. 2 on transforming growth factor-β and insulin-induced collagen formation in lung fibroblasts. J. Biol. Chem. 264: 16988-16991.
71. Green, J. A., R. A. Stockton, C. Johnson, and B. S. Jacobson. 2004. 5-Lipoxygenase and cyclooxygenase regulate wound closure in NIH/3T3 fibroblast monolayers. Am. J. Physiol. 287: C373-C383.
72. 2 production. Am. J. Pathol. 165: 1663-1676.
73. Moore, B. B., M. J. Coffey, P. Christensen, S. Sitterding, R. Ngan, C. A. Wilke, R. McDonald, S. M. Phare, M. Peters-Golden, R. Paine, and G. B. Toews. 2000. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostagland-independent mechanism. J. Immunol. 165: 4032-4039.
74. -/- mice: implications for fibroproliferation. Am. J. Physiol. 284: L1103-L1111.